Join BJS Academy
BJS Academy>Randomized clinical ...>Sentinel lymph node ...
Normal View Dyslexic View

Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment

18 October 2023
Randomized clinical trials Breast
Tinterri C, Canavese G, Gatzemeier W, Barbieri E, Bottini A, Sagona A et al, for the SINODAR-ONE Collaborative Group.

Br J Surg 2023; 110: 1143-1152.

After a median of 33 months, there were five recurrence is in each group, none in the axilla. Five-year recurrence-free, and overall survival rates were also similar. It was decided to continue enrolment into the study.

Comment: An important study, but low outcome rates threaten its power, so the authors have taken the unusual (but sensible) step of reopening it.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct079
Randomized clinical trials
Randomized clinical trials
Breast
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment
Tinterri C, Canavese G, Gatzemeier W, Barbieri E, Bottini A, Sagona A et al, for the SINODAR-ONE Collaborative Group.
18102023
Br J Surg 2023; 110: 1143-1152.
After a median of 33 months, there were five recurrence is in each group, none in the axilla. Five-year recurrence-free, and overall survival rates were also similar. It was decided to continue enrolment into the study.
Comment: An important study, but low outcome rates threaten its power, so the authors have taken the unusual (but sensible) step of reopening it.
Published on: 18 October 2023
Article ID: rct079

Related articles

Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.

Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.

16 August 2024

21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.
N Engl J Med 2021; 385: 2336-2347

1 January 2022

Event-free survival with pembrolizumab in early triple-negative breast cancer.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.
N Engl J Med 2022; 386: 556-567.

1 March 2022
Home
  • Normal view
  • Dyslexic view
Info
Copied!